세계의 오피오이드 사용 장애(OUD) 시장

Global Opioid Use Disorder Market to Reach US$10.6 Billion by 2030

The global market for Opioid Use Disorder estimated at US$5.7 Billion in the year 2024, is expected to reach US$10.6 Billion by 2030, growing at a CAGR of 10.9% over the analysis period 2024-2030. Buprenorphine Drug, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Naltrexone Drug segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 9.8% CAGR

The Opioid Use Disorder market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.8% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Opioid Use Disorder Market - Key Trends & Drivers Summarized

Why Is Opioid Use Disorder a Persistent Global Health Crisis Demanding Scalable Interventions?

Opioid Use Disorder (OUD) has escalated into a major public health emergency worldwide, particularly in North America, where synthetic opioids such as fentanyl have driven unprecedented overdose rates. The chronic, relapsing nature of OUD and its widespread socio-economic consequences have led to urgent calls for comprehensive treatment infrastructure and long-term care solutions. While awareness of the epidemic has grown significantly, so has the complexity of the crisis, which involves not only illicit drug use but also the over-prescription of opioids for pain management. With millions affected globally, healthcare systems are under pressure to adopt integrated, multi-modal approaches combining medication-assisted treatment (MAT), behavioral therapy, harm reduction, and social support. The stigma surrounding addiction, gaps in healthcare access, and the criminalization of substance use continue to hinder effective intervention strategies. However, increased public health funding, greater availability of treatment centers, and shifting perceptions of addiction as a treatable medical condition are fostering a more supportive environment for recovery. In this context, the market for OUD treatments is expanding as governments, healthcare providers, and private sector players prioritize scalable, evidence-based solutions that address both the physiological and psychological aspects of opioid dependency.

How Are Advancements in Treatment Modalities Shaping Recovery Outcomes?

The therapeutic landscape for Opioid Use Disorder is rapidly evolving, with innovation focused on improving the efficacy, safety, and accessibility of treatment options. Medication-assisted treatments (MATs) remain the cornerstone of OUD management, with methadone, buprenorphine, and naltrexone being widely used to reduce cravings, block opioid effects, and support recovery. Recent years have seen the development of extended-release formulations and implantable devices that ensure sustained medication delivery, reduce dosing frequency, and improve adherence-critical factors in long-term recovery. Novel combination therapies are also emerging to address both opioid dependence and co-occurring conditions such as depression or anxiety. Digital therapeutics and telehealth-based counseling platforms are gaining ground, especially post-COVID-19, enabling remote monitoring, therapy access, and adherence tracking. Wearable biosensors and mobile apps that provide real-time feedback and relapse alerts are being explored to support patients outside clinical environments. Additionally, research into vaccines and antagonists that block opioid receptors before the drug can exert its effects is progressing, holding promise for future prevention strategies. These advancements are not only improving patient outcomes but are also expanding treatment options in underserved and rural areas, where traditional infrastructure may be lacking.

What Systemic and Regional Factors Are Influencing Market Demand and Accessibility?

The demand for Opioid Use Disorder treatment solutions varies significantly across regions due to differences in healthcare infrastructure, policy frameworks, and socio-cultural attitudes toward addiction. In the United States and Canada, where the opioid crisis has reached epidemic levels, the focus is on expanding access to MAT, harm reduction services like naloxone distribution and safe injection sites, and integrating OUD treatment into primary care and emergency services. These countries have also seen strong government funding and regulatory support for new treatment products, including fast-tracked approvals and reimbursement programs. In contrast, developing nations often face limited access to both opioids for pain management and OUD therapies due to restrictive drug policies and underfunded healthcare systems. Stigma remains a barrier worldwide, often deterring individuals from seeking treatment or governments from investing in addiction care. However, global initiatives by organizations such as the WHO and UNODC are driving awareness and capacity-building efforts, particularly in Eastern Europe, Latin America, and parts of Asia. Meanwhile, criminal justice reforms in several countries are redirecting drug users toward treatment instead of incarceration, thereby expanding institutional demand for OUD solutions. These regional disparities and policy shifts are playing a pivotal role in shaping where and how the market for OUD treatment products and services is developing.

What Are the Primary Forces Driving Growth in the Opioid Use Disorder Market?

The growth in the Opioid Use Disorder market is driven by several factors related to rising disease prevalence, evolving treatment paradigms, technology integration, and policy shifts. A critical driver is the increasing global incidence of opioid addiction and related deaths, which is prompting urgent healthcare interventions and sustained public health funding. The widespread acceptance of medication-assisted treatment as the gold standard for OUD care is driving demand for methadone, buprenorphine, and naltrexone products, especially long-acting injectable formulations that improve adherence. Expansion of telehealth services is making treatment more accessible, particularly in rural and underserved communities, while digital platforms are facilitating patient engagement, therapy scheduling, and medication management. Regulatory support, including fast-track drug approvals, expanded prescribing authority for non-specialist providers, and insurance reimbursement reforms, is accelerating market penetration. Pharmaceutical innovation is also playing a key role, with companies investing in abuse-deterrent formulations, implants, and novel delivery methods to improve patient outcomes. Additionally, the decriminalization of substance use and the growing use of OUD treatment in correctional health systems are generating new institutional demand. Public-private partnerships and global awareness campaigns are further mobilizing resources and expanding the availability of OUD treatment across various healthcare settings. Collectively, these forces are fostering a robust, multi-faceted market environment focused on long-term recovery and systemic resilience.

SCOPE OF STUDY:

The report analyzes the Opioid Use Disorder market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Buprenorphine Drug, Naltrexone Drug, Methadone Drug, Other Drugs); Route of Administration (Injectable Route of Administration, Oral Route of Administration, Other Route of Administrations); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

• Acadia Healthcare
• Alkermes plc
• Amneal Pharmaceuticals, Inc.
• BioDelivery Sciences International Inc.
• Camurus AB
• Collegium Pharmaceutical
• Hikma Pharmaceuticals PLC
• Indivior PLC
• Johnson & Johnson
• Lannett Company, Inc.
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Omeros Corporation
• Opiant Pharmaceuticals, Inc.
• Orexo AB
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Titan Pharmaceuticals, Inc.
• Viatris Inc. (Mylan N.V.)
• West Pharmaceutical Services, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Opioid Use Disorder - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Escalating Overdose Rates Throw the Spotlight on Urgent Need for Scalable Opioid Use Disorder (OUD) Treatments
  • Rising Prevalence of Synthetic Opioids Like Fentanyl Spurs Growth in Medication-Assisted Treatment (MAT) Adoption
  • Policy Reforms and Federal Funding Initiatives Expand Addressable Market Opportunity for MAT Providers and Drug Developers
  • Integration of Telehealth in Behavioral Health Services Strengthens the Business Case for Remote OUD Treatment Models
  • Advancements in Long-Acting Injectables and Implants Drive Adoption of Adherence-Focused Treatment Solutions
  • Co-Occurrence of Mental Health Disorders Accelerates Demand for Integrated, Dual-Diagnosis Treatment Programs
  • Criminal Justice System Reforms Generate Opportunities for OUD Intervention in Correctional and Community Settings
  • Widening Provider Authorization and Prescribing Flexibility Propels Growth in Buprenorphine-Based Therapies
  • Increased Public Awareness and Stigma Reduction Campaigns Sustain Growth in Patient-Initiated Treatment Uptake
  • Digital Therapeutics and Mobile Recovery Apps Drive Innovation in Continuous OUD Support and Relapse Prevention
  • Growing Role of Pharmacies and Primary Care Clinics in MAT Delivery Expands Treatment Accessibility Across Communities
  • Emergence of Precision Medicine in Addiction Care Strengthens Development of Personalized OUD Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Opioid Use Disorder Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Opioid Use Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Opioid Use Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Buprenorphine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Buprenorphine Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Naltrexone Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Naltrexone Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Methadone Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Methadone Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Injectable Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Injectable Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Oral Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Other Route of Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 24: USA Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 25: USA 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: USA 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
• CANADA
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Canada 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Canada 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
• JAPAN
  • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Japan 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Japan 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
• CHINA
  • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 42: China Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: China 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 46: China Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: China 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
• EUROPE
  • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 49: Europe 6-Year Perspective for Opioid Use Disorder by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Europe 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 54: Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
• FRANCE
  • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 58: France Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: France 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 60: France Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: France 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
• GERMANY
  • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Germany 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 66: Germany Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Germany 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Italy 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 72: Italy Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Italy 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
• UNITED KINGDOM
  • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 76: UK Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: UK 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 78: UK Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: UK 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Rest of Europe 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Rest of Europe 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
• ASIA-PACIFIC
  • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Asia-Pacific 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of World 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Rest of World 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Rest of World 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030

IV. COMPETITION